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ABSTRACT 
 
Pilot Study: 
Objective: To characterize the elution of platinum from carboplatin-impregnated calcium sulfate 
hemihydrate (CSH) beads in vitro. 
Sample:  Sixty carboplatin- impregnated CSH beads and 9 CSH beads without added carboplatin 
(controls)  
Procedures: Carboplatin-impregnated CSH beads (each containing 4.6 mg carboplatin [2.4 mg 
platinum]) were placed into separate 10 mL plastic tubes containing 5 mL of PBS in groups of 1, 
3, 6, or 10; 3 control beads were placed in a single tube of PBS at the same volume. Experiments 
were conducted in triplicate at 37 °C and pH 7.4 with constant agitation. Eluent samples were 
collected at 1, 2, 3, 6, 12, 24, and 72 hours. Samples were analyzed for platinum content by 
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS).  
Results: The mean concentration of platinum released per carboplatin- impregnated bead over 72 
hours was 445.3 mg/L. Cumulative concentrations of platinum eluted increased as the number of 
beads per tube increased. There was a significant difference in platinum concentrations over 
time, with values increasing over the first 12 hours and then declining for all tubes. There was 
also a significant difference in percentage of total incorporated platinum released into tubes with 
different numbers of beads: the percentage eluted of platinum was higher in tubes containing 1 or 
3 beads than in those containing 6 or 10 beads. 
Conclusions and Clinical Relevance: Carboplatin-impregnated CSH beads eluted platinum 
over 72 hours. Further studies are needed to determine whether implantation of carboplatin-
impregnated CSH beads results in detectable levels of platinum systemically and whether the 
platinum concentrations eluted locally are toxic to tumor cells.  
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Experiment 2:  
Objective: To characterize the long-term elution of platinum from carboplatin-impregnated CSH 
beads in vitro using two distinct sampling methods. 
Sample: Carboplatin-impregnated CSH beads containing 4.6 mg carboplatin/bead 
Procedures: Method 1: Three carboplatin- impregnated CSH beads were placed into 10 mL 
plastic tubes with 5 mL of PBS at 37 C and pH 7.4 with constant agitation. PBS was sampled by 
evacuation of all 5 mL eluent at 1, 2, 3, 6, 9, and 12 hours and 1, 2, 3, 6, 9, 12, 15, 18, 22, 26, 
and 30 days. The fluid was then replaced with 5 mL of fresh PBS at each time point. Method 2: 
Tubes corresponding to each sampling time were established at time zero, with each tube 
containing 3 carboplatin-impregnated CSH beads and 5 mL PBS. PBS was sampled from only 
the assigned tubes at each time point by evacuation of all 5 mL eluent. Control beads without 
carboplatin were also evaluated using both methods. Samples were analyzed for platinum 
concentration by ICP-MS.   
Results: Platinum was released from carboplatin- impregnated CSH beads for 22-30 days. There 
were significant differences in platinum concentrations and percentage of total incorporated 
platinum released over time and between methods. 
Conclusions and Clinical Relevance: Carboplatin-impregnated CSH beads eluted platinum for 
22-30 days. Sampling method significantly affected platinum release from carboplatin-
impregnated CSH beads at nearly all time points. Results from sampling Method 1 and Method 2 
provide estimations of the minimum and maximum platinum concentrations expected to elute 
from carboplatin- impregnated CSH beads in vivo. 
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CHAPTER 1 
REVIEW OF THE LITERATURE 
 
 
Carboplatin as a chemotherapeutic agent in veterinary patients: 
 
 
Carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) is a second generation, 
platinum-containing chemotherapeutic agent. Like other platinum agents, it works by binding 
and cross-linking DNA, resulting in non-cell-cycle-dependent tumor cell lysis. It was originally 
developed for humans in an attempt to mitigate the adverse effects of cisplatin, including nausea, 
vomiting, nephrotoxicity, neurotoxicity and myelosuppression. This decrease in toxicity is likely 
due to slower tissue binding and metabolism. The dose-limiting toxicity in dogs and cats is 
myelosupression characterized by neutropenia and thrombocytopenia.1,2 The dose currently 
administered to dogs is 300 mg/m2, and is based on the maximally tolerated dose with an 
acceptable level of toxicosis.3 In cats, the maximally tolerated dose has been found to be 240 
mg/m2,4 although dosing based on targeted area under the platinum concentration-versus time 
curve and individual glomerular filtration rate in cats may more accurately predict and minimize 
carboplatin-associated myelotoxicosis.5  
 
In 1988, Gaver and others evaluated the disposition of carboplatin in the beagle dog. The authors 
determined that after administration of various doses of carboplatin between 3-24 mg/kg (65-580 
mg/m2), the peak plasma concentration of bound platinum occurred between 4 and 6 hours, and 
by 96 hours a mean of 70%  10% of the dosed platinum was excreted in the urine, with the 
majority of this excretion occurring within the first 24 hours.2  
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Carboplatin has been shown to be an effective therapy for delaying metastasis of canine 
osteosarcoma. In a study performed in 1996 by Bergman et al, 48 dogs were treated by limb 
amputation and up to 4 doses of carboplatin. In this study, the median disease-free-interval was 
8.6 months and median survival time was 10.7 months. Thirty-four percent of dogs were alive at 
one year.6 These results were not significantly different from previous studies using 2-4 doses of 
adjuvant cisplatin or a combination of cisplatin and doxorubicin.7,8 A more recent study 
performed by Selmic and others in 2014 compared 5 different chemotherapy protocols following 
amputation for osteosarcoma (carboplatin every 21 days for 4 or 6 cycles, doxorubicin every 14 
or every 21 days for 5 cycles, and alternating carboplatin and doxorubicin every 21 days for 3 
cycles). There was no significant difference in disease-free interval or survival time among 
protocols, and the protocols with carboplatin as a sole agent resulted in a lower proportion of 
dogs experiencing adverse events, which could allow patients to maintain a higher quality of life 
during treatment.9  
 
Melanoma is the most common oral malignancy in dogs. A study conducted in 2012 evaluated 
carboplatin as an adjuvant treatment for melanoma after surgical excision. The overall survival in 
this study was 440 days,10 compared to 90-120 days following conservative surgical excision 
alone and 273-297 days following aggressive surgical excision ( 1 cm margin).11-14 In a study 
evaluating carboplatin as the sole treatment for macroscopic oral melanoma, overall response 
rate was found to be 28%, with 24% of dogs having a partial response lasting a median of 165 
days.15 Another study from 2013 indicated that carboplatin may be an effective treatment for 
some patients with gross disease for which surgery is not an option.16 These findings suggest that 
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carboplatin may be an effective single treatment or adjunctive treatment for oral melanoma in 
dogs.  
 
A study completed in 2002 evaluated clinical presentation and response to therapy for dogs with 
anal sac adenocarcinoma. Partial remission was recorded in 30% of dogs treated with 
carboplatin, indicating that carboplatin likely has antitumor activity in cases of canine apocrine 
gland adenocarcinoma.17 In this study, the effect of carboplatin treatment on overall survival was 
not evaluated. A later study conducted in 2013 did not find a statistically significant difference in 
overall survival between dogs with surgically excised anal sac apocrine gland carcinoma with or 
without adjuvant carboplatin; however, this was a retrospective study, and limitations and bias 
inherent to these types of studies may have skewed the results.18   
 
Local delivery systems: 
 
Sesame oil 
One of the earliest attempts to utilize a sustained local delivery system for carboplatin 
administration involved combining carboplatin with sesame oil. This formulation was first used 
in veterinary patients to treat dermal tumors in horses. Four injections at a mean dose of 0.97 mg 
of cisplatin/cm3 were administered directly into the tumor at 2-week intervals. Tumor regression 
was noted in all cases with minimal local toxicity. Mean relapse-free intervals were 21.6 months 
and 14 months for horses with sarcoid and carcinoma/papilloma, respectively.19 In a study 
performed in 1996, a sesame oil-carboplatin emulsion was injected intralesionally in cats with 
squamous cell carcinoma of the nasal planum. Four weekly intratumoral chemotherapy injections 
of carboplatin (100 mg/m2 of body surface area) injected with or without purified sesame oil, or 
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injections of carboplatin suspended in purified sesame oil (1.5 mg/cm3 of tissue) were 
administered to cats with advanced stage tumors. It was found that formulations of carboplatin 
suspended in purified sesame oil significantly reduced systemic exposure to carboplatin and drug 
leakage from the site of injection.20 
 
Plachitin 
Another local delivery system, a combination of chitin and cisplatin (Plachitin), has been 
implanted in mice experimentally to treat Ehrlich tumor, a type of mammary adenocarcinoma. In 
this study, high cisplatin concentrations were measured in the tissue around the implant for 
greater than 8 weeks with no signs of nephrotoxicity in the subjects. Peak concentrations 
occurred at 4 weeks after implantation.21 Local application of Plachitin also significantly 
improved survival.22 This same delivery system was used intraperitoneally in humans with non-
curative gastrointestinal neoplasia, and was considered to be safe and effective when used in this 
manner.23 
 
Atrigel 
Atrigel is a system that consists of a resorbable polymer in a biocompatible carrier. Upon 
administration, the polymer undergoes a phase change from a liquid to a formed implant. Release 
periods of 1 week to 4 months have been achieved.24 The earliest study evaluating this delivery 
system combined the substrate with cisplatin in healthy beagle dogs and found variable local 
tissue toxicity, with 38% of injections resulting in some form of local tissue reaction. Only 3 of 
these reactions were severe, resulting in draining tract formation and tissue necrosis. No systemic 
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toxicity was noted, and serum platinum concentrations were seen to peak at 2 days following 
administration, gradually declining to day 30.25  
 
One study evaluated the local and systemic toxicity as well as the platinum pharmacokinetics in 
dogs with stage IIb appendicular osteosarcoma after 4 subcutaneous injections of 70 mg/m2 or 
100 mg/m2 of cisplatin in Atrigel. Local toxicity was variable, and systemic toxicity was not 
noted. However, during this study it was discovered that dimethyl sulfoxide, which is the solvent 
used in the co-polymer system, may inactivate cisplatin and render the system ineffective. This 
supposition was supported by the fact that the disease-free interval was decreased in this study 
when compared with traditional chemotherapy.26 
 
Nonetheless, this system was later tried for use with soft tissue sarcomas of the canine extremity. 
Nineteen dogs with histologically confirmed soft tissue sarcomas of the extremities were treated 
with a combination of marginal surgery and Atrigel administration. The median dose of 
cisplatin was 52.1 mg/m2. Wound complications were noted in 84.2% of dogs. Forty-seven 
percent of dogs were alive at the time of analysis (874 days post- treatment) with local 
recurrence being noted in 16.6% of dogs.27 This may be considered a favorable result; however, 
recurrence rate of low-grade spindle cell sarcomas of the distal extremities with marginal 
excision and without adjuvant therapy has been shown to be low (10.8%), indicating that the 
administration of Atrigel may have minimal effect on local recurrence.28  
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OPLA-Pt 
Porous, solid, biodegradable polymer sponges, particularly open-cell polylactic acid (OPLA) 
sponges, have been impregnated with platinum-containing chemotherapeutic agents and 
implanted at various sites for local tumor control. Open-cell polylactic acid impregnated with 
cisplatin (OPLA-Pt) was first used in canine patients in a study conducted in 1992. Bilateral 
intercalary femoral allografts were implanted in 6 normal beagle dogs. OPLA-Pt was implanted 
adjacent to the allograft in one femur, and the polymer without cisplatin was implanted adjacent 
to the allograft in the other femur. The mean peak total serum platinum concentration was low 
when compared with that attained after a single intravenous bolus of cisplatin; however the area 
under the curve for total serum platinum concentration versus time for the first 21 days was large 
in comparison, indicating that sustained release of cisplatin can be delivered safely with this 
system. Local effects were minor, with moderate swelling and edema noted within 24 hours after 
surgery in 3 legs and resolving after 7 days. Radiographic healing was noted in all but one limb 
by 3 months after surgery.29  
 
The first clinical trial performed in dogs to evaluate the effect of OPLA-Pt on overall survival 
evaluated its use in conjunction with radiation therapy to treat malignant nasal tumors. Thirteen 
dogs were treated with a combination of OPLA-Pt implanted intramuscularly at a distant site and 
megavoltage radiation. No systemic toxicity was noted, and local tissue reactions were seen in 
only 2 dogs. The overall survival time was longer (580 days) in this study group when compared 
with a group of historical controls that received radiation alone (325 days). This difference was 
found to be significant on multivariate analysis, indicating that this combination treatment may 
favorably affect survival of dogs with nasal tumors.30  
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A study performed in 1997 evaluated the effect of OPLA-Pt placed in the wound bed of 
marginally resected soft tissue sarcomas in 30 dogs. The implant was removed from 28% of sites 
due to local wound complication, and the rate of recurrence (31%) was comparable to previous 
reports of soft tissue sarcoma treated by marginal resection and radiotherapy, indicating that this 
system may not be ideal for this application.31 
 
Later, this system was used clinically in conjunction with limb-sparing surgery to treat canine 
osteosarcoma.  In this study, 80 dogs with osteosarcoma were treated by limb-sparing surgery 
and were randomized to receive an OPLA implant either with or without cisplatin. The dogs also 
received 4 doses of adjuvant cisplatin chemotherapy. Although the difference did not quite reach 
statistical significance (p=0.071), dogs in the OPLA-Pt group were 53.5% less likely to develop 
local recurrence than dogs in the control group, indicating that local tumor recurrence may be 
decreased after limb-sparing surgery by use of OPLA-Pt.32 
 
PMMA 
Polymethyl methacrylate (PMMA) is a tissue-compatible cement that has been evaluated for use 
as a depot for sustained release of cisplatin. In one study, PMMA was fashioned into cylinders, 
impregnated with 20 mg of cisplatin, and implanted into subcutaneous tissue over the thorax in 
healthy dogs. Cylinders without cisplatin were implanted on the contralateral side as negative 
controls. Plasma samples were obtained before implantation and at various time points during the 
study. Tissue chamber samples were also obtained for platinum determination.  Clinical 
laboratory testing was performed to evaluate for systemic toxicity, and necropsy was performed 
at the termination of the study. Platinum concentrations at the treated sites and plasma platinum 
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concentrations were found to be significantly greater than control and pretreatment samples at 
the majority of the time points evaluated; however, no local or systemic adverse reactions were 
noted. 33 
 
There have been more extensive studies evaluating PMMA as a method of providing local 
delivery of antibiotics to chronically infected wounds. In 1998, Dernell and others evaluated the 
use of PMMA beads implanted with tobramycin and vancomycin to treat severe infections 
associated with limb sparing surgery. In 67% of dogs, clinical signs of infection resolved in a 
median of 4 weeks.34 In 1997, PMMA impregnated with amikacin, gentamicin, tobramycin or 
cefazolin was used in horses with open or infected fractures repaired with internal fixation or 
external coaptation devices. Fracture union was achieved in 15 of 19 horses in this study, 
indicating that these beads may have been helpful in controlling local infection.35 In people, 
PMMA has been used for decades as a means of providing local antibiotic therapy to compound 
fractures. A study conducted in 1993 by Ostermann and others found that fractures treated with 
systemic antibiotic prophylaxis alone had an overall infection rate of 17%, while fractures treated 
with both systemic and local antibiotic therapy had an infection rate of only 4.2%. Thus, use of 
antibiotic- laden PMMA beads in addition to systemic antibiotic may prevent infectious 
complications in compound fractures.36  
 
Calcium sulfate hemihydrate:  
Calcium sulfate hemihydrate is a biocompatible material that is also biodegradable, inexpensive, 
readily available, and sterilizable by γ- radiation. A study performed in 2000 evaluated the rate 
of degradation of calcium sulfate hemihydrate beads both with and without cisplatin in equine 
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tissue. In this study, control beads and beads containing cisplatin were implanted into the 
cervical subcutaneous tissues of the necks of 6 healthy horses. One control bead was harvested 
every 7 days for a total of 35 days. Mild swelling and edema were noted over and around the 
bead until the 5th post-operative day. The matrix material was evident on histopathology up to 7 
days in 1 horse, 14 days in 3 horses, and 21 days in 2 horses. The lesions surrounding the beads 
progressed from necrosuppurative inflammation to granulomatous inflammation and fibrosis, 
with the most severe inflammation being present at 7 days.  Degradation of the beads appeared to 
occur through phagocytosis by multinucleated giant cells and macrophages. At 28 days, only 
residual inflammation and focal areas of fibrosis remained.a  
 
In 2006, cisplatin-containing calcium sulfate beads were implanted in horses for the treatment of 
cutaneous neoplasia. Types of tumors treated included sarcoid, fibrosarcoma, fibroma, peripheral 
nerve sheath tumor, squamous cell carcinoma, melanoma, lymphosarcoma, adenocarcinoma, and 
basal cell tumor. Eighty-three percent of animals for which long-term follow-up was available 
were relapse free 2 years after treatment and adverse effects were minimal, suggesting that 
implantation of these beads may be an effective treatment for various equine cutaneous 
neoplasms.37 
 
Calcium sulfate beads impregnated with platinum-containing agents have also been evaluated in 
the treatment of canine soft tissue sarcomas. An unpublished study conducted by Hess and others 
evaluated outcome after implantation of cisplatin or carboplatin-containing calcium sulfate beads 
at the site of wide resection of soft tissue sarcomas. Local reactions were mild and consisted of 
seroma formation, cellulitis, swelling and erythema. Overall disease-free-interval was not 
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reached in this study, and only 5 tumors recurred locally, indicating that these beads, in addition 
to being well tolerated, might improve local control for canine soft tissue sarcoma.b  More 
recently, a study was published by Bergman and others evaluating cisplatin- impregnated calcium 
sulfate bead placement after marginal excision of soft tissue sarcomas in dogs. Local reactions in 
this study occurred in less than 50% of dogs and were most often classified as mild or moderate. 
Twenty-nine percent of tumors recurred. Median disease-free interval was not reached for grades 
1 and 2 soft tissue sarcomas and was 148 days for dogs with grade 3 sarcomas. These results 
were favorable and further support that calcium sulfate beads containing platinum agents may 
play a role in local control of soft tissue sarcomas.38  
 
Elution studies in veterinary medicine: 
 
Elution is the extraction of a solute from a material by washing with a solvent. Elution studies 
are useful in characterizing the in vitro release characteristics of local delivery systems. Although 
no studies to date have been performed evaluating the elution of carboplatin from either PMMA 
or calcium sulfate, there have been numerous studies evaluating the elution of various antibiotics 
from these materials.  
 
In 2000, Ethell and others evaluated the elution of gentamicin, amikacin and ceftiofur from 
PMMA and hydroxyapatite cement (HAC). Historical sampling methods were utilized, wherein 
all of the eluent fluid was sampled and replaced at each time point. The authors found that the 
rate of elution for all beads was greatest within the first 24 hours, and the total antibiotic 
concentration released from beads over 30 days was significantly greater from HAC than from 
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PMMA. However, both gentamicin- and amikacin- impregnated PMMA and HAC released 
bacteriocidal concentrations of antibiotic for at least 30 days, indicating that this method allows 
for sustained local release of therapeutic levels of antibiotic locally. Ceftiofur-impregnated beads 
eluted reasonable concentrations of antibiotic for the first 3 to 7 days, but concentrations then 
decreased rapidly.39  
 
Later, Phillips and others evaluated the release of amikacin and cefazolin, both separately and 
together in the same bead, from PMMA. The authors found that when amikacin or cefazolin 
were incorporated into beads independently, they each eluted concentrations greater than the 
MIC for selected bacteria over the 30-day study period. However, when these compounds were 
combined into a single bead, a significantly shorter duration of elution resulted, indicating that 
co-elution of amikacin and cefazolin from PMMA cannot be recommended for sustained 
treatment of infection. When individual beads of each antibiotic are used alone, however, each is 
likely to be clinically effective. 40 
 
Calcium sulfate has also been shown to be an effect depot of antibiotic release in vitro. In 2003, 
Santschi and McGarvey evaluated the elution of gentamicin from CSH beads.  Gentamicin was 
released over the entire 14-day study period, with 80% of release occurring over the first 48 
hours. The eluent fluid from the beads was evaluated against cultures of E coli bacteria, and was 
found to inhibit bacterial growth at all time points. The authors also determined that the beads 
retained bacteriocidal activity after ethylene oxide sterilization and storage at room temperature 
for up to 5 months.41  
 
  12 
In 2010, Atilla and others evaluated the release of amikacin and vancomycin from CSH beads 
and the effect of eluent fluid on inhibition of growth of Staphylococcus spp. In this study, 
amikacin elution was rapid, and only inhibited bacterial growth for <24 hours. However, 
vancomycin elution occurred more slowly and inhibited growth for 56 days when eluting alone, 
or 5 days when eluting with amikacin. The authors concluded that local treatment with 
vancomycin- impregnated CSH beads would likely be clinically effective, while treatment with 
amikacin- or amikacin and vancomycin- impregnated beads likely required further study due to 
concerns over efficacy.42  
 
Finally, in 2015, Phillips and others evaluated the elution of clindamycin and enrofloxacin from 
CSH beads. Based on MIC values for clindamycin against bacteria commonly infecting wounds 
in dogs and cats, clindamycin did not elute concentrations sufficient to inhibit growth of bacteria. 
However, enrofloxacin eluent concentrations were maintained sufficiently above the MIC for 
common wound pathogens of dogs and cats, indicating that enrofloxacin- impregnated CSH 
beads may be an effective local treatment for susceptible bacterial infections. An additional 
interesting finding was that enrofloxacin exhibited a unique release pattern resulting in steady, 
sustained release of the antibiotic. Such a release pattern is different from most others seen in 
previous studies with other antibiotics, where release initially occurs rapidly, and then continues 
at a lower rate for the duration of the study period.43  
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Fluid exchange in tissues and sampling methods:  
 
In humans, approximately 2/3 of the extracellular fluid volume is contained in the skin and 
skeletal muscle. It has been found that this fluid is likely completely exchanged every 24-48 
hours in healthy individuals.44 However, fluid exchange is altered substantially by processes such 
as inflammation, neoplasia, fibrosis or surgical intervention. 45,46 To date, elution studies have 
employed a sampling method in which the entirety of the eluent volume is exchanged at each 
sampling time.40,42,43,47-60 However, it is likely that this sampling method dose not accurately 
mimic the fluid dynamics of the altered in vivo conditions in which impregnated beads are 
typically implanted.  
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CHAPTER 2 
ELUTION OF PLATINUM FROM CARBOPLATIN-IMPREGNATED CALCIUM SULFATE 
HEMIHYDRATE BEADS: PILOT STUDY 
 
Introduction: 
 
Carboplatin (cis-diammine-1,1-cyclobutane dicarboxylate platinum II) is a second-generation, 
platinum-containing chemotherapeutic agent that has been safely used in dogs and cats and is 
reported to have less severe nephrotoxic and emetogenic effects than cisplatin. 1-3Additionally, 
recent studies1,4-11 have demonstrated cytotoxicity of carboplatin against appendicular 
osteosarcoma and oral malignant melanoma in dogs as well as oral and cutaneous squamous cell 
carcinoma in cats.  
 
The adverse effects associated with platinum-based chemotherapeutics include nephrotoxicosis, 
myelosuppressive effects such as neutropenia and thrombocytopenia, and gastrointestinal effects 
such as nausea, vomiting, and inappetence.4,12-14 To decrease the incidence of toxicosis and 
adverse events in treated patients, local, intralesional, and targeted chemotherapeutic protocols 
for use of cisplatin and carboplatin have been developed to treat local disease.4,12-20 Results of 
several investigations suggest that direct chemotherapy, or intratumoral injection of a single, 
systemic dose of chemotherapeutic agent, may be associated with short duration of action and 
substantial uptake into the bloodstream. 1,21-23 In contrast, delivery systems allowing sustained, 
local release of a chemotherapeutic agent for the treatment of local disease offer the advantage of 
achieving high concentrations at the tumor site with minimal to no systemic toxicosis.12-21,24 In 
dogs, some sustained-release delivery systems have efficacy against appendicular osteosarcoma 
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and nasal tumors (cisplatin) as well as soft tissue sarcomas (carboplatin).15,20,24-27 However, these 
delivery systems are not commercially available, have been associated with unacceptable 
regional toxic effects including development of wound dehiscence and local infection, or have 
resulted in equivocal clinical improvement.15,18,20,24 
 
Carboplatin-impregnated calcium sulfate hemihydrate (CSH) beads are a commercially available 
drug delivery system for sustained release of carboplatin and can be implanted at sites of grossly 
evident tumor or of marginal tumor extirpation.  A proven depot for drug release, 28-33 CSH is 
biodegradable, biocompatible, inexpensive, readily available, and sterilizable by γ-irradiation. 
Published studies22,34 and anecdotal reportsa have shown promising results for cisplatin-and 
carboplatin- impregnated biodegradable beads as treatment for various tumors in horses and soft 
tissue sarcomas in dogs. However, to the authors’ knowledge, no published data exist regarding 
the rate, pattern, and duration of elution of platinum from commercially available carboplatin-
impregnated CSH beads.   
 
The purpose of the study reported here was to evaluate whether platinum elutes from 
carboplatin- impregnated CSH beads and, if so, to determine the initial pattern of release of 
platinum.  We hypothesized that platinum would elute from carboplatin- impregnated CSH beads 
into PBS at concentrations greater than the peak plasma concentration reported in dogs following 
administration of a single IV dose of carboplatin (300 mg/m2 of body surface area).2,4 We also 
hypothesized that the concentration of platinum in the eluent would be positively associated with 
the number of carboplatin- impregnated beads placed together in a sample tube. 
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Materials and methods:  
 
Carboplatin-impregnated beads were created at an accredited compounding pharmacy.b Briefly, a 
forged metal bead mold with a synthetic polytetrafluoroethylene-based coatingc was used to 
create chains of uniform, 3 mm diameter beadsd containing either 4.6 mg of carboplatin (2.4 mg 
of platinum) with 18.4 mg of CSH or 23.0 mg of CSH (used as a control); both formulations 
included dextran (at a final concentration of 0.67 mg/bead; added to slow release of the agent).  
 
All beads were formed and evaluated in triplicate (groups A, B, C).  For each experiment, 
carboplatin- impregnated CSH beads were placed in individual 10 mL plastic tubes in groups of 
1, 3, 6, or 10 with 5 mL of PBS, and 3 control beads were placed together in another tube with 
the same volume of PBS. The tubes were maintained at 37 C and pH of 7.4 with constant 
agitation. The eluent was sampled by evacuation of all 5 mL of the PBS solution at 1, 2, 3, 6, 12, 
24 and 72 hours (with the initial placement of the beads in solution considered time 0).  The 
evacuated fluid was replaced with 5 mL of fresh PBS at each time point. Eluent samples were 
analyzed for platinum content by inductively coupled plasma-mass spectrometry (limit of 
detection, 0.1 ppm).e 35 Beads were monitored for signs of dissolution, including grossly 
discernible changes to the surface of the bead, opacity of the eluent, or accumulation of 
particulate matter in the eluent.  
 
Statistical analysis: 
 
Distribution of continuous data was evaluated by means of a Shapiro-Wilk test, assessment of 
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skewness and kurtosis, and Q-Q plots. Data that were normally distributed (hour 1through hour 
24) were reported as mean, standard deviation (SD), and minimum-maximum (range). 
Nonnormally distributed data were reported as median, 10th to 90th percentiles, and range.  
Estimated marginal mean  SEM data and 95% confidence intervals were reported for normally 
distributed data over time.  Nonnormally distributed data were log-transformed for parametric 
analysis. A repeated measures general linear model was used to determine whether there was a 
difference in platinum concentrations in the eluent fluid over time (within subjects), by triplicate 
group A, B, or C (between subjects), and by number of beads per tube (between subjects). This 
was also done for evaluation of the percentage of total incorporated platinum eluted by the beads. 
A Mauchly test for sphericity was used to evaluate the homogeneity of covariance. Because the 
homogeneity of covariance was violated, the Greenhouse-Geisser method was used to interpret 
the results. The total amount of platinum released by each bead was calculated by adding the 
total milligrams of platinum released over 72 hours and dividing by the number of beads. A one-
way ANOVA was then used to determine if there was a difference in the amount of platinum 
released per bead among groups containing different numbers of beads. A commercially 
available statistical software programf was used to analyze the data. Values of P < 0.05 were 
considered significant. 
 
Results: 
 
There was a significant (P < 0.001) difference in platinum concentrations in the eluents for 
carboplatin-containing beads over time, with amounts increasing over the first 12 hours and then 
declining thereafter for all tubes (Figure 2.1). Control beads did not elute detectable levels of 
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platinum at any time point. There was also a significant (P < 0.001) difference in the total 
amount of platinum released over 72 hours when results were compared for tubes containing 
different numbers of carboplatin-impregnated beads, with mean platinum concentrations in the 
eluent increasing significantly with increasing number of beads per tube (estimated marginal 
means: 1 bead, 63.4 mg/L; 3 beads, 201.3 mg/L; 6 beads, 377.7 mg/L; 10 beads, 609.3 mg/L) 
(Figure 2.1). There was no significant (P = 0.974) difference in platinum concentrations of the 
eluents among triplicate groups A, B and C.  
 
The mean  SD concentration of platinum released per bead over 72 hours was 445.3  31.5 
mg/L (range, 390.0 to 509.1 mg/L). There was no significant (P = 0.488) difference in amount of 
platinum released per bead when results for all beads over all time points were compared. There 
was, however, a significant (P < 0.001) difference in the percent of total incorporated platinum 
released over time, with the values for all time points significantly different from one another 
(Table 2.1). There was also a significant (P = 0.001) difference in the percentage of total 
incorporated platinum released into tubes with different numbers of beads, with the percentage of 
platinum eluted significantly higher in tubes with 1- or 3-beads than in tubes with 6- or 10-beads 
(Table 2.2). After 12 hours, 89%, 87%, 79%, and 67% of the incorporated platinum had been 
released in the tubes with 1, 3, 6, and 10 beads, respectively (Figure 2.2). At 72 hours, 92%, 
97%, 91%, and 88% of the incorporated platinum had been released in the tubes with 1, 3, 6, and 
10 beads, respectively (Figure 2.2). Control beads did not elute detectable levels of platinum at 
any point in time.  
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Grossly, the beads showed minor changes consistent with dissolution over the study period. By 
24 hours, the surface of the beads appeared slightly roughened and the eluent appeared slightly 
cloudy on aspiration. These changes had subjectively progressed slightly by 72 hours, but the 
beads did not completely dissolve nor disintegrate substantially over the study period.  
 
Discussion: 
 
Carboplatin exerts its antitumor effects by binding and cross-linking DNA, resulting in non-cell 
cycle dependent tumor cell lysis.3,12 It was developed as a safer alternative to cisplatin, and is an 
effective agent against solid tumors in dogs and cats.2,4,5 Specifically, it has been found to be 
useful in treating osteosarcoma, oral melanoma, and anal sac adenocarcinoma.1,4-10,36,37 
Carboplatin is typically administered IV, but it can also be given subcutaneously, 
intraperitoneally and intratumorally. The primary dose-limiting toxic effect of the drug is 
myelosuppression characterized by neutropenia and thrombocytopenia.1,3,4,12-14  
 
The doses of carboplatin administered to dogs and cats are determined on the basis of the 
maximally tolerated dose (ie. the highest dose associated with an acceptable degree of 
toxicosis).4 For dogs, the typical dosage is 300 mg of carboplatin/m2 of body surface area, IV, 
every 21 days. This dose achieves a peak plasma concentration of approximately 80 mg of 
carboplatin (42.1 mg platinum)/L 4 to 6 hours after IV administration.2,4 In the present study, 
carbopatin-impregnated beads in all tubes (1, 3, 6, or 10 beads) eluted concentrations of platinum 
greater than or equal to this peak plasma concentration for ≥ 12 hours, indicating that these beads 
should be at least as effective locally against local tumor cells as a single dose of carboplatin IV. 
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Concerning strategies for local chemotherapy, there have been 2 studies evaluating the effect of 
carboplatin directly on canine tumor cell lines and the IC50 of the drug in vitro.7,38 Determination 
of IC50 values for dose-effect testing of drugs has been used to assess efficacy of 
chemotherapeutic agents in human and veterinary medicine.7,39-41 In the in vitro studies, 7,38 with 
canine tumor cell lines, the IC50s for mammary carcinoma, melanoma, and transitional cell 
carcinoma at 72 hours were found to be between 2.2 and 11.3 mg carboplatin/L (1.2 to 5.9 mg 
platinum/L). In our study, platinum concentrations were greater than these values for the entire 
72 hour period in all tubes with carboplatin impregnated beads except those containing only 1 
bead, suggesting that implantation of ≥ 3 beads in a tumor bed may effectively inhibit growth of 
these tumors. However, the duration for which platinum concentrations must be sustained above 
a minimal concentration to achieve long-term tumor control is not currently known. The IC50s 
appeared to be time-dependent in the study of mammary carcinoma cells, decreasing by > 50% 
between 24 and 72 hours for carboplatin, indicating that tumor cell susceptibility may increase 
over time.7 Additional studies are needed to determine the time period for which such a 
concentration must be maintained.  
 
In the present study, platinum release increased rapidly during the first 12 hours and declined 
thereafter. Burst release, a phenomenon of initial rapid release of a compound from a substrate, is 
characteristic of elution of various compounds from CSH and polymethylmethacrylate beads, 
with 50 to 90% of total elution often occurring in the first 24 hours.28-30,42,43 Burst release has 
been attributed to diffusion of the impregnated, hydrophilic compound from the exposed surface 
of the beads into the surrounding eluent.12,17,31 Subsequent release occurs as a result of diffusion 
of the compound along the concentration gradient between the center and periphery of the 
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bead.32,33,44 Complete release of the compound occurs upon dissolution of biodegradable 
substrates such as CSH, and release may continue until complete dissolution has 
occurred.12,31,32,45-47 However, it is not known whether burst release of a chemotherapeutic agent 
is desirable for tumor control, and the ideal rate, pattern and duration of elution of platinum from 
any substrate have yet to be determined. The burst effect was diminished and release of 
compound more sustained when CSH beads were wrapped with either porcine small intestinal 
submucosa or biodegradable poly lactide-co-glycolide.31,48 Additionally, carboplatin poly (L-
lactide) microspheres have been dispersed in a thermosensitive biodegradable gel to prevent 
burst release and to prolong total release.12 It has been suggested that wrapping the beads or 
dispersing them in gel diminishes the increase in porosity that occurs upon dissolution, thus 
protecting the CSH construct from further dissolution by the eluent.12,31,48  
 
When evaluating over all time points, there was a significant difference in the percentage of total 
platinum eluted into tubes containing different numbers of beads. The percentage of total 
incorporated platinum eluted was significantly higher in tubes that contained 1 or 3 beads than 
those that contained 6 or 10 beads when all time points were compared. This difference was most 
notable early in the study; 89 and 86%, respectively, of incorporated platinum was eluted into the 
tubes with 1 and 3 beads during the first 12 hours, as compared to only 79 and 67%, respectively, 
in the tubes with 6 and 10 beads.  This difference in burst release among bead groups may have 
been attributable to the physical presence of more beads in the tubes with 6 and 10 beads. The 
beads were placed in 5 mL of PBS within a conical test tube, and beads typically clustered and 
settled at the base of the tube. As the number of beads per tube increased, less of the total surface 
area of the beads would be exposed to the surrounding eluent owing to clustering of the beads. 
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As the initial release of compound from a bead is thought to occur via diffusion of the compound 
from the exposed surface of the bead, a decrease in the exposed surface area of the beads in the 
tubes with 6 and 10 beads may have resulted in slower initial release of platinum. It is possible 
that platinum was released more rapidly from beads in these groups once dissolution of the beads 
began, equalizing release among all bead groups over the entire study period. Consequently, over 
the 72-hour period evaluated, the mean ± SD concentration of platinum released per bead was 
445.34  31.5 mg platinum/L, regardless of the number of beads in the tube. This information 
may have added benefit once concentrations of carboplatin necessary for local tumor control and 
diffusion characteristics in living tissues are known, and could be used to help determine how 
many beads should be implanted into a tumor bed in future clinical research. 
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Footnotes: 
 
a  Hess T, Miller J, Fettig A, et al. “Treatment of Canine Subcutaneous Soft Tissue Sarcomas 
With Surgical Excision and Intraoperative Placement of Platinum-Containing Biodegradable 
Beads”, Veterinary Cancer Society Annual Conference (Las Vegas, NV). October 18-21, 2012. 
b Wedgewood Pharmacy, Swedesboro, NJ 
c University of Vermont Instrumentation and Modeling Facility, Burlington, VT 
d Matrix III, US Patent 6391336, Royer Biomedical Inc, Frederick, MD 
e Midwest Laboratories, Inc., Omaha, NE 
f SPSS version 23.0, SPSS Inc., Armonk, NY 
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Figures and tables:  
Figure 2.1: 
 
Cumulative platinum concentration (mean ± SD of triplicate experiments) in the eluent of 
carboplatin- impregnated CSH beads placed in groups of 1 (blue bars), 3 (red bars), 6 (green bars), 
or 10 (black bars) into tubes of PBS (pH, 7.4) at 37oC. Each bead contained 4.6 mg of carboplatin 
(2.4 mg of platinum) and 18.4 mg of CSH with dextran. Initial placement of the beads into solution 
was considered time 0; all eluent was removed for analysis and replaced with 5 mL of fresh PBS 
at each time point. 
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Figure 2.2: 
 
 
Cumulative percentage (mean ± SD of triplicate experiments) of the total incorporated platinum 
eluted from carboplatin- impregnated CSH beads into PBS at predetermined time points (same 
sample as in Figure 1). See Figure 1 for remainder of key. 
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Table 2.1:  
 
Time Mean (%) SD (%) Range (%) 
1 hour 14.93  4.31 8.54-22.11 
2 hours 30.26 6.37 21.27-39.92 
3 hours 43.56 7.20 33.04-54.36 
6 hours 62.18 9.65 48.18-78.33 
12 hours 80.99 10.58 66.59-102.50 
24 hours 88.95 9.17 74.02-105.14 
72 hours 92.06 6.46 80.62-105.19 
Mean percentage of the total incorporated platinum eluted from carboplatin- impregnated CSH 
beads into PBS at predetermined time points, irrespective of group. Concentrations at all times 
differed significantly from each other (all P<0.0001; except 24 h vs 72 h, p=0.054) 
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Table 2.2:  
 
Group 
Mean ± SEM 
(%) 
95% CI 
(%) 
1 bead 65.0 ± 1.78 *† 60.9–69.1 
3 beads 63.6 ± 1.78 ‡§ 59.5–67.7 
6 beads 57.7 ± 1.78 *‡║ 53.6–61.8 
10 beads 49.5 ±1.78 †§║ 45.4–53.6 
Cumulative percentage of total platinum content eluted from carboplatin- impregnated CSH beads into 
PBS across all time points. Beads were placed in 5 mL of PBS (pH 7.4) at 37oC in groups of 1, 3, 6, or 
10 for 72 hours. 
*P = 0.02. †P < 0.001. ‡P = 0.048. §P = 0.001, ║P = 0.012 
CI = Confidence interval.   
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CHAPTER 3 
CHARACTERIZATION OF LONG-TERM ELUTION OF PLATINUM FROM 
CARBOPLATIN-IMPREGNATED CALCIUM SULFATE HEMIHYDRATE BEADS IN 
VITRO BY TWO DISTINCT SAMPLING METHODS 
 
Introduction: 
 
Local, sustained- release chemotherapeutic strategies have been developed to decrease the 
incidence of systemic toxicity while optimizing regional control of non-resectable, incompletely 
or marginally resected tumors.1-10 However, many of these delivery systems are not 
commercially available, have resulted in unacceptable regional complications, or have 
demonstrated minimal improvement in clinical outcome.5,8,10,11  
 
Carboplatin-impregnated calcium sulfate hemihydrate beads are a commercially availablea 
delivery system for sustained release of the platinum-containing agent, carboplatin.  Calcium 
sulfate hemihydrate (CSH) is a proven biodegradable carrier for drug release and causes minimal 
reaction in tissues.12-18 Published studies19 and anecdotal reportsa have shown promising efficacy 
of cisplatin-and carboplatin- impregnated biodegradable beads against various tumors in horses 
and soft tissue sarcomas in dogs, with negligible local side effects compared to other carriers. 
We described the short-term elution characteristics of carboplatin- impregnated CSH beads based 
on findings of an in vitro pilot study.20 
 
Elution is the practice of extracting one material from another by washing it with a solvent. This 
process has been used historically as an in vitro method to predict the theoretical efficacy of 
antibiotic- and chemotherapeutic-impregnated carriers for sustained release of these compounds 
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in chronically infected wounds or tumor beds, respectively.15,18,21 Studies evaluating elution 
characteristics have most commonly employed a sampling method in which the entirety of the 
eluent volume is exchanged at each sampling time.12,15,18,21-34  
 
In humans, the skin and skeletal muscle contain approximately 2/3 of the extracellular fluid 
volume, combined. Available evidence suggests that interstitial fluid in normal skin and skeletal 
muscle is completely exchanged every 24-48 hours.35 However, if the tissues are significantly 
disrupted by inflammation, neoplasia, fibrosis, or surgical intervention, the normal exchange of 
fluid is altered.36,37 It is likely that the most commonly used sampling method does not 
adequately mimic the fluid dynamics of these altered in vivo conditions. To date, no elution 
studies have taken into account the differences in dynamics of fluid exchange between normal 
and disrupted tissues.   
 
The purpose of this study was to characterize the long-term elution of platinum from carboplatin-
impregnated CSH beads by comparing two distinct methods of sampling: one that mimics an 
environment with rapid and complete fluid exchange, and one that mimics an environment where 
no fluid exchange occurs. We hypothesized that sampling of eluent by the two distinct methods 
would result in significant differences in platinum concentrations in the measured eluent 
samples. An additional objective was to use the platinum concentration measured in this study to 
define the minimum and maximum concentrations of platinum that could be expected to elute 
from carboplatin- impregnated CSH beads in any in vivo condition.   
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Materials and methods: 
 
All carboplatin- impregnated beads evaluated in this study were created at an accredited 
compounding pharmacy.b   Briefly, a forged metal bead mold with a synthetic 
polytetrafluoroethylele-based coatingc was used to create chains of uniform, 3 mm diameter 
beadsd containing either 4.6 mg carboplatin (2.4 mg of platinum) with 18.4 mg CSH or 23.0 mg 
of CSH (used as a control); both formulations included dextran (at a final concentration of 0.67 
mg/bead; added to slow release of the agent).  
 
All beads were formed and evaluated in triplicate (groups A, B, C) for Sampling Methods 1 and 
2.  For Method 1, three carboplatin- impregnated CSH beads were placed in a tube containing 5 
mL of PBS and maintained at 37 Celsius and pH 7.4 with constant agitation (Figure 3.1). The 
PBS was sampled from the beads by evacuation of all 5 mL of the eluent fluid at 1, 2, 3, 6, 9, and 
12 hours, and 1, 2, 3, 6, 9, 12, 15, 18, 22, 26, and 30 days. The fluid was then replaced with 5 mL 
of fresh PBS at each time point (Figure 3.2). Control beads without carboplatin were also 
evaluated using this sampling method.  
 
For Method 2, tubes corresponding to each sampling time point (1, 2, 3, 6, 9, and 12 hours, and 
1, 2, 3, 6, 9, 12, 15, 18, 22, 26, and 30 days) were established at time zero, with each tube 
containing 3 carboplatin-impregnated CSH beads and 5 mL PBS (Figure 3.3). Ambient 
conditions were the same as described for Method 1. The PBS was sampled from only the 
assigned tubes at each time point by evacuation of all 5 mL of the eluent fluid (Figure 3.4). 
Control beads without carboplatin were also evaluated using this sampling method.   
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Samples from Method 1 were compared with samples from Method 2. Also, the first 72 hours of 
samples from Method 1 were compared with samples from a previously conducted 72-hour pilot 
study that also utilized Method 1. All eluent samples from Method 1 and Method 2 and the pilot 
study were analyzed for platinum concentration by inductively coupled plasma-mass 
spectrometry (ICP-MS; limit of detection, 0.1 parts per million).e 
 
Statistical methods: 
 
The distribution of the data was evaluated by means of a Shapiro-Wilk test, skewness, kurtosis, 
and q-q plots. Data that were normally distributed were reported as mean, standard deviation 
(SD), and minimum-maximum (range) values, while non-normally distributed data were reported 
by median, 25th to 50th percentiles, and range. Data that were not normally distributed were log 
transformed for parametric testing. A general linear model for repeated measures was used to 
determine if there was a difference in platinum concentrations over time (1 h, 2 h, 3 h, 6 h, 12 h, 
1 d, 3 d) and by group (present study vs. pilot study). This same statistical test was used to 
compare Methods 1 and 2 over time (1 h, 2 h, 3 h, 6 h, 9 h, 12 h, 1 d, 2 d, 3 d, 6 d, 9 d, 12 d, 15 
d, 18 d, 22 d, 26 d, 30 d). Mauchly’s test was used to assess sphericity. Because sphericity was 
not found, the Greenhouse-Geisser test was used to determine within subjects effects. A 
commercial statistical software programf was used to analyze the data. A p <0.05 was used to 
determine statistical significance.    
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Results: 
 
There was a significant difference in platinum concentrations over time when evaluating the first 
72 hours of samples evaluated by Method 1 (F = 34.3, P = 0.0001), but no difference was found 
between samples from the pilot study and the first 72 hours of Method 1 samples from the 
present study (F = 0.105, P = 0.762).  
 
Regarding Methods 1 and 2 of the present study, there were significant differences in platinum 
concentrations released over time (F = 58.77, P = 0.0001) and between methods (F = 264576.20, 
P = 0.0001) (Table 3.1). Platinum concentrations (mg/L) measured by Method 2 were 
significantly higher (all p < 0.01) than concentrations measured by Method 1 for all times except 
1 hour (p = 0.495) (Figure 3.5).  
 
There were significant differences in the percent mg of incorporated platinum released over time 
(F = 78.13, P = 0.0001) and between methods (F = 12290.48, P = 0.0001) (Table 3.2). The 
percent mg of total incorporated platinum that was released over time was significantly higher 
for samples measured by Method 2 (all p < 0.01) than those measured by Method 1 for all times 
except hour (p = 0.487). 
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Discussion: 
 
Calcium sulfate hemihydrate has been extensively studied as a drug delivery substrate and is a 
proven depot for drug release, or elution.12-17 Drug elution studies should evaluate species-
specific in vivo pharmacokinetics and pharmacodynamics, but inherent in such studies are risks 
to the species involved and significant costs.38 Review of the literature, therefore, reveals an 
emphasis on in vitro evaluation of drug elution and variability in study design.12-18,21-34 One 
consistency among in vitro studies is the use of a sampling method that involves complete 
exchange of eluent medium such as PBS or canine serum.12,15,18,21-34 Although some investigators 
removed only an aliquot of eluent for drug measurement and replenished the same volume using 
fresh medium,2,4,39 only one investigative team attempted to mimic in vivo conditions by 
exchanging a diminishing volume of eluent over the course of the study.13 However, this 
component of the study design was based solely on the authors’ clinical impression that wound 
effusion diminishes over time, a supposition that does not apply to all wounds.13  
 
As the most commonly used sampling method could promote more rapid elution by creating a 
new concentration gradient at each sampling time, the authors of the present study used two 
distinct sampling methods to evaluate platinum release from carboplatin- impregnated CSH 
beads. Comparing results of the two sampling methods allowed the authors to 1) characterize the 
long-term elution of platinum from commercially available carboplatin- impregnated CSH beads 
and 2) define a range of platinum concentrations that could be expected to elute in different in 
vivo conditions. 
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Delivery systems allowing sustained, local release of a chemotherapeutic agent for the treatment 
of neoplasia offer the advantage of achieving high concentrations at a tumor site with minimal 
risk of systemic toxicity.2-11,18,21 Elution of substrate-bound drugs in tissue is largely dependent 
on the distribution of the drug, or concentration gradient, between the substrate and the 
biological tissue40.  The shape, size, and porosity of the substrate carrier are also important12-18,21-
34. Distribution, absorption, and elimination of the drug are then mediated by the drug’s 
extracellular concentration and the vascularity, lymphatic density, cellular microenvironment, 
and fluid dynamics of the wound bed36,37,40-42. Inflammatory or neoplastic infiltrations or surgical 
intervention could sufficiently alter the tissue environment to result in variation in drug 
distribution, absorption, and elimination among patients.36,37 In patients with a normal tissue 
microenvironment and interstitial fluid dynamics, complete exchange of extracellular fluid might 
be expected to occur quite frequently, often within hours.36 However, in patients with significant 
inflammatory, neoplastic, or fibrous tissue infiltration, little to no exchange of extracellular fluid 
may occur, or exchange of fluid might occur very slowly.36,37  
 
In the present in vitro study, sampling Method 1 involved complete exchange of eluent at every 
time point to more closely mimic a wound environment where rapid and complete extracellular 
fluid exchange would be expected. Results of Sampling Method 1, therefore, represent the 
minimum concentration of platinum that would be expected to occur in vivo. Sampling Method 2 
involved no exchange of eluent, and mimicked a wound environment where fluid exchange 
would be expected to be negligible. Therefore, results of Sampling Method 2 represent the 
cumulative release of platinum into the surrounding medium over time and the maximum 
concentration of platinum that would be expected to occur in vivo. Because wounds or tumor 
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beds will vary among dogs and cats in size, vascularity, severity of inflammation, and rate and 
proportion of wound fluid exchange, the actual concentration of platinum eluted in vivo from 
carboplatin- impregnated CSH beads should fall within the range of these minimum and 
maximum values. 
 
Recommended dosages for carboplatin are currently dictated by the systemic maximally 
tolerated dosage, not by targeted plasma or tissue concentration.1 Currently, carboplatin 
chemotherapy for dogs involves a carboplatin dosage of 300 mg/m2 of body surface area 
administered IV every 21 days. A single IV dose achieves a peak plasma concentration (PPC) of 
approximately 80 mg of carboplatin (42.1 mg platinum)/L 4-6 hours following IV 
administration.1,43 In the present study, platinum concentrations measured by Methods 1 and 2 
were maintained over 1.3 times the PPC for up to 24 hours and from 1.3-15 times the PPC for up 
to 30 days for Methods 1 and 2, respectively.  
 
Only two studies that have investigated targeted tissue concentrations by evaluating the effect of 
carboplatin directly on canine tumor cells.44,45 These studies determined the 50% inhibitory 
concentration (IC50), or the concentration of carboplatin necessary to achieve 50% inhibition of 
replication of tumor cells in vitro. Determination of IC50 values for dose-response testing of 
drugs has been used to assess efficacy of carboplatin in human and veterinary studies.44-48 In 
these studies, the IC50s for mammary carcinoma, melanoma, and transitional cell carcinoma at 72 
hours were between 2.2-11.3 mg carboplatin/L (1.2-5.9 mg platinum/L). Although platinum 
concentrations measured by Method 2 were maintained 13-90 times above IC50 values from 1 
hour to 30 days, platinum concentrations measured by Method 1 fell below IC50 values between 
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48 and 72 hours. This discrepancy highlights the importance of accurate modeling in in vitro 
studies.  IC50 concentrations appear to be time-dependent, and the duration for which platinum 
concentrations must be sustained above some minimal concentration to achieve tumor control is 
not known.44-48 Further studies are needed to evaluate the interval and longer-term IC50s of 
carboplatin for various susceptible tumor types and the ideal rate, pattern, and duration of 
platinum elution from carboplatin- impregnated CSH beads. 
 
The minimum and maximum platinum concentrations that could be expected to elute from 
individual carboplatin- impregnated CSH beads from 1 hour to 30 days are listed in Table 3.3. 
The actual concentration eluted will depend on the physical environment of the wound or tumor 
bed. These values are median values of experiments performed in triplicate, and are derived from 
measurement of platinum elution by sampling Method 1 (minimum concentration) and sampling 
Method 2 (maximum concentration). These measurements may prove clinically useful once IC50s 
for local tumor control are known. It should be noted that these concentrations are derived from 
an in vitro study, and are therefore only estimates of concentrations that will be achieved in vivo. 
The accuracy of these estimations depends on the accuracy with which our sampling methods 
model the two most extreme wound or tumor bed conditions. Further studies are needed 
comparing the findings of our in vitro study with tissue concentrations of platinum measured in 
vivo.  
 
The sampling Method 1 used in this study was also used in a preliminary study conducted by the 
authors.20 The pilot study evaluated platinum elution from carboplatin-impregnated CSH beads 
over 72 hours from the same manufacturerb over 72 hours. When platinum elution measured 
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during the pilot study was compared with the first 72 hours of elution measured by sampling 
Method 1 in the present study, there was a significant difference in platinum concentrations over 
time, but not between the pilot study and the present study. This finding indicates precision in 
sampling as well as consistency in total bead platinum concentration among beads with different 
manufacturer lot numbers. 
 
Significant differences were found when comparing concentrations of platinum measured by 
Methods 1 and 2 for nearly all time points (Figure 5). The mg/L of platinum and the percent mg 
of platinum incorporated into each bead that were released by each time point were significantly 
different from nearly every other time point, indicating that neither a constant amount nor a 
constant proportion of platinum were released by each sampling time (Table 3.1 and Table 3.2). 
Platinum release did increase sharply in the first 24 hours of sampling for Method 1, and 
declined thereafter, a phenomenon known as “burst release” in elution studies.12-18,21-34 
Interestingly, a burst of release was not noted for sampling Method 2, as substantial proportions 
of the total incorporated mg platinum were released until the 12th study day (Table 3.2). This 
finding raises the question whether the phenomenon of burst release is actually an artifact of 
sampling Method 1 because at each sampling point with this method, a new gradient is created 
between the bead and freshly added PBS containing no drug at all. 
 
Sampling method significantly affected the concentrations of platinum released from 
carboplatin- impregnated CSH beads at nearly all time points. A sampling method that involves 
frequent and complete exchange of eluent fluid may mimic a wound bed environment with 
normal vascularity, cellularity, and fluid dynamics but may not accurately apply to clinical 
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situations. Elution profiles of local drug delivery systems measured by this sampling method 
may not be reliably applied to patients. Further studies are needed comparing in vitro elution 
profiles of drugs with pharmacokinetic and pharmacodynamic profiles obtained from in vivo 
studies. 
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b Wedgewood Pharmacy, Swedesboro, NJ  
c University of Vermont Instrumentation and Modeling Facility, Burlington, VT  
d Matrix III, US Patent 6391336, Royer Biomedical Inc, Frederick, MD  
e Midwest Laboratories, Inc., Omaha, NE  
f SPSS version 23.0, SPSS Inc., Armonk, NY 
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Figures and tables: 
 
 
Figure 3.1:  
 
 
 
Experimental set-up for Method 1. Three carboplatin- impregnated CSH beads were placed in an 
eluent well containing 5 mL of PBS and maintained at 37 Celsius and pH 7.4 with constant 
agitation. 
 
  50 
Figure 3.2:  
 
 
 
 
Experimental design for Method 1. The PBS was sampled from the beads by evacuation of all 5 
mL of the eluent fluid at 1, 2, 3, 6, 9, and 12 hours, and 1, 2, 3, 6, 9, 12, 15, 18, 22, 26, and 30 
days. The fluid was then replaced with 5 mL of fresh PBS at each time point. 
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Figure 3.3:  
 
 
 
Experimental set-up for Method 2. Tubes corresponding to each sampling time point were 
established at time zero, with each tube (Time 1 hr, Time 2 hrs, Time 3 hrs, …) containing 3 
carboplatin- impregnated CSH beads and 5 mL PBS. 
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Figure 3.4:  
 
 
 
Experimental design for Method 2. The PBS was sampled from only the assigned tubes at each 
time point by evacuation of all 5 mL of the eluent fluid. 
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Figure 3.5:  
 
 
 
Platinum concentrations (mean ± SD of triplicate experiments) eluted from carboplatin-
impregnated CSH beads into PBS (pH 7.4, 37oC) at predetermined time points over time, as 
sampled by Methods 1 and 2. Each bead contained 4.6 mg of carboplatin (2.4 mg of platinum) 
and 18.4 mg of CSH with dextran. Initial placement of the beads into solution was considered 
time 0. Method 1 is depicted in orange with data points represented by diamonds, while Method 
2 is depicted in dark blue with data points represented by squares.  
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Table 3.1: Comparison of platinum concentrations (mg/L) that were measured over time in 
eluent by sampling Methods 1 and 2. 
Time  Group  Median 25-50% Min-Max   
1 houra                1       255.0  243-255 243-284 
                           2                   252.0  242-252 242-258 
2 hourb               1                    253.0  228-253 228-258 
 2  341.0  328-341 328-348 
3 hourc 1  237.0   213-237 213-240 
 2  370.0  367-370 367-382 
6 hourd 1  258.0  247-258 247-305 
 2  521.0  492-521 492-524 
9 houre 1  196.0  170-196 170-208 
 2  586.0  586-586 586-617 
12 hourf 1  203.0  147-203 720-775 
 2  722.0  720-722 720-775 
1 dayg  1  180.0  63.5-180 63.5-289 
 2  1022.0  970-1022 970-1023 
2 daysh 1  17.2  3.10-17.2 3.10-20.7 
 2  1350.0  1350-1350 1350-1364  
3 daysi 1  0.48  0.190-0.480 0.190-0.490 
 2  1586.0  1485-1586 1485-1763 
6 daysj 1  0.26  0.250-0.260 0.250-0.270 
 2  1671.0  1651-1671 1651-1852 
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Table 3.1 (continued):  
9 daysk 1  0.18  0.170-0.180 0.170-0.190 
 2  1857.0  1709-1857 1709-1940 
12 daysl 1  0.14  0.110-0.140 0.110-0.190 
 2  1794.0  486-1794 1486-1943 
15 daysm 1  0.10  0.0900-0.100 0.0900-0.150 
 2  1792.0  1687-1792 1687-1995 
18 daysn 1  0.09  0.000-0.0900 0.000-0.120 
 2  1741.0  1714-1741 1714-1756 
22 dayso 1  0.07           0.000-0.0700 0.000-0.0900   
 2  1790.0       1711-1790 1711-1796 
26 daysp 2  1657.0  1596-1657 1596-1693 
30 daysq 2  1601.0  1557-1601 1557-1757 
a1 hour significantly different (p<0.05) from all times, except day 1 (p=0.111) 
b2 hour significantly different (p<0.05) from all times, except 3 hour (p=0.712) and day 1 
(p=0.228) 
c3 hour significantly different (p<0.05) from all times, except 3 hour (p=0.712) and day 1 
(p=0.293) 
d 6 hour significantly different (p<0.05) from all times, except 9 hour (p=0.202), 12 hour 
(p=0.989), and  day 1 (p=0.855) 
e 9 hour significantly different (p<0.05) from all times, except 6 hour (p=0.202), 12 hour 
(p=0.330), and  day 1 (p=0.597) 
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Table 3.1 (continued): 
f 12 hour significantly different (p<0.05) from all times, except 6 hour (p=0.989), 9 hour 
(p=0.330), and day 1 (p=0.824) 
g 1 day significantly different (p<0.05) from all times, except 1 hour (p=0.111), 2 hour 
(p=0.228), 6 hour (p=0.855), 9 hour (p=0.597), and 12 hour (p=0.824) 
h 2 day significantly different (p<0.05) from all times, except day 18 (p=0.06) and day 22 
(p=0.06) 
i 3 day significantly different (p<0.05) from all times, except day 6 (p=0.507), day 9 (p=0.192), 
day 18 (p=0.730) and day 22 (p=0.655) 
j 6 day significantly different (p<0.05) from all times, except day 3 (p=0.507), day 18 (p=0.846) 
and day 22 (p=0.722) 
k 9 day significantly different (p<0.05) from all times, except day 3 (p=0.192), day 12 (p=0.257), 
day 15 (p=0.07), day 18 (p=0.846) and day 22 (p=0.990) 
l 12 day significantly different (p<0.05) from all times, except day 9 (p=0.257), day 15 
(p=0.216), day 18 (p=0.648) and day 22 (p=0.792) 
m 15 day significantly different (p<0.05) from all times, except day 9 (p=0.07), day 12 (p=0.216), 
day 18 (p=0.469) and day 22 (p=0.620) 
n 18 day significantly different (p<0.05) from all times, except day 2 (p=0.06), day 3 (p=0.730), 
day 6 (p=0.846), day 9 (p=0.846), day 12 (p=0.648), day 15 (p=0.469), day 22 (p=0.147), day 26 
(p=0.128), and day30 (p=0.129) 
o 22 day significantly different (p<0.05) from all times, except day 2 (p=0.06), day 3 (p=0.655), 
day 6 (p=0.722), day 9 (p=0.990), day 12 (p=0.792), day 15 (p=0.620), day 18 (p=0.147), day 26 
(p=0.129), and day30 (p=0.130) 
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Table 3.1 (continued): 
p 26 day significantly different (p<0.05) from all times, except day 18 (p=0.128), day 22 
(p=0.129), day 26 (p=0.128), and day 30 (p=0.814) 
q 30 day significantly different (p<0.05) from all times, except day 18 (p=0.128), day 22 
(p=0.129), day 26 (p=0.130), and day 30 (p=0.814) 
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Table 3.2: Comparison of percent of total platinum incorporated that was measured in eluent 
over time by sampling Methods 1 and 2.  
Time  Method  Median 25-50% Min-Max   
1 houra                1       17.6  16.8-17.6 16.6-19.6 
                           2                   17.4   16.7-17.4 16.7-17.8 
2 hourb                1                   17.4   15.7-17.4 15.7-17.8 
 2  23.5  22.6-23.5 22.6-24.0 
3 hourc 1  16.3   14.7-16.3 14.7-16.6 
 2  25.5  25.3-25.5 25.3-26.3  
6 hourd 1  17.8  17.0-17.8 17.0-21.0 
 2  35.9  33.9-35.9 33.9-36.1 
9 houre 1  13.5  11.7-13.5 11.7-14.3 
 2  40.4  40.4-40.4 40.4-42.6 
12 hourf 1  14.0  10.1-14.0 10.1-15.0 
 2  49.8  49.7-49.8 49.7-53.4 
1 dayg  1  12.4  4.37-12.41 4.37-19.93 
 2  70.5  66.9-70.5 66.9-70.6 
2 daysh 1  1.18  0.21-1.18 0.21-1.42 
 2  93.1  93.1-93.1 93.1-94.1  
3 daysi 1  0.03  0.013-0.03 0.01-0.03 
 2  109  102-109 102-122 
6 daysj 1  0.017  0.017-0.017 0.017-0.018  
 2  115  114-115 114-128 
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Table 3.2 (continued):  
9 daysk 1  0.012  0.011-0.012 0.011-0.013 
 2  128  118-128 118-134 
12 daysl 1  0.009  0.007-0.009 0.007-0.013 
 2  124  102-124 102-134 
15 daysm 1  0.006  0.006-0.006 0.006-0.10 
 2  124  116-124 116-138 
18 daysn 1  0.006  0.00-0.006 0.00-0.008 
 2  120  118-120 118-121 
22 dayso 1  0.004        0.00-0.004 0.00-0.006 
 2  123    118-123 118-124 
26 daysp 2  114  110-114 110-117 
30 daysq 2  110  107-110 107-121 
a1 hour significantly different (p<0.01) from all times 
b2 hour significantly different (p<0.01) from all times, except 3 hour (p=0.357) 
c3 hour significantly different (p<0.01) from all times, except 2 hour (p=0.357) 
d 6 hour significantly different (p<0.01) from all times, except 9 hour (p=0.872) 
e 9 hour significantly different (p<0.01) from all times, except 6 hour (p=0.872) 
f 12 hour significantly different (p<0.01) from all times 
g 1 day significantly different (p<0.05) from all times 
h 2 day significantly different (p<0.05) from all times 
i 3 day significantly different (p<0.05) from all times, except day 9 (p=0.183), day 12 (p=0.485), 
day 18 (p=0.146), day 22 (p=0.073), day 26 (p=0.753), and day 30 (p=0.846) 
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Table 3.2 (continued):  
j 6 day significantly different (p<0.05) from all times, except day 9 (p=0.444), day 12 (p=0.908), 
day 15 (p=0.076), day 18 (p=0.839), day 22 (p=0.533), day 26 (p=0.445), and day 30 (p=0.424) 
k 9 day significantly different (p<0.05) from all times, except day 3 (p=0.183), day 9 (p=444), 
day 12 (p=0.628), day 15 (p=0.946), day 18 (p=0.257), day 22 (p=0.406), and day 30 (p=0.102) 
l 12 day significantly different (p<0.05) from all times, except day 3 (p=0.485), day 6 (p=0.908), 
day 9 (p=0.628), day 15 (p=0.653), day 18 (p=0.978), day 22 (p=0.883), day 26 (p=0.523), and 
day 30 (p=0.302) 
m 15 day significantly different (p<0.05) from all times, except day 6 (p=0.076), day 9 (p=0.946), 
day 12 (p=0.653), day 18 (p=0.329), day 22 (p=0.466), day 26 (p=0.212), and day 30 (p=0.243) 
n 18 day significantly different (p<0.05) from all times, except day 3 (p=0.146), day 6 (p=0.839), 
day 9 (p=0.257), day 12 (p=0.978), day 15 (p=0.329), day 22 (p=0.166), day 26 (p=0.093), and 
day 30 (p=0.239) 
o 22 day significantly different (p<0.05) from all times, except day 3 (p=0.073), day 6 (p=0.533), 
day 9 (p=0.406), day 12 (p=0.883), day 15 (p=0.466), day 18 (p=0.166), day 26 (p=0.087), and 
day 30 (p=0.221) 
p 26 day significantly different (p<0.05) from all times, except day 3 (p=0.753), day 6 (p=0.445), 
day 12 (p=0.523), day 15 (p=0.212), day 18 (p=0.093), day 22 (p=0.087), and day 30 (p=0.841)  
q 30 day significantly different (p<0.05) from all times, except day36 (p=0.846), day 6 
(p=0.424), day 9 (p=0.102), day 12 (p=0.302), day 15 (p=0.243), day 18 (p=0.239), day 22 
(p=0.2221), day 26 (p=0.841) 
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Table 3.3: The minimum and maximum platinum concentrations expected to elute from 
individual carboplatin- impregnated CSH beads in vivo. 
 
Time    Range of platinum (mg/L) eluted per bead 
   Minimum  Maximum 
1 hour   84.0   85.0   
2 hour                                      84.3    114 
3 hour   79.0    123  
6 hour   86.0   174 
9 hour   65.3   195  
12 hour   67.7   241 
1 day    60.0   341 
2 days   5.73   450   
3 days   0.160   529 
6 days   0.0867   557 
9 days   0.0600   619  
12 days   0.0467   598   
15 days   0.0334   597 
18 days   0.0300   580 
22 days   0.0234   597   
26 days   0   552 
30 days   0   534 
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CHAPTER 4 
FUTURE DIRECTIONS 
 
 
Carboplatin-impregnated CSH beads are a delivery system for sustained release of carboplatin 
and are intended for implantation at sites of gross tumor or of marginal tumor extirpation. 
Calcium sulfate hemihydrate is a proven depot for drug release, is biodegradable, biocompatible, 
inexpensive, and sterilizable.1-3 Published studies and unpublished reports have shown promising 
efficacy of cisplatin-and carboplatin-impregnated CSH beads against various tumors in horses 
and soft tissue sarcomas in dogs without clinically significant local or systemic toxicity.1,a 
Moreover, carboplatin- impregnated CSH beads are commercially available and affordable, at a 
cost of only $90 per three beads. To date, no studies exist evaluating the safety and efficacy of 
carboplatin- impregnated CSH beads in cats. 
 
Feline injection site-associated sarcoma (FISAS) is reported to develop at sites of vaccination, 
subcutaneous injection, or microchip implantation, with prevalence ranging from 1 to 1.3 per 
1000 vaccinated cats.4-11 It is estimated that at least 66 million felines comprise the household cat 
population in the United States, and over 40% of these cats receive at least 1 vaccine per year, 
creating a sizable population of cats at risk.4 Despite changes in vaccines and vaccination 
protocols performed in an attempt to mitigate occurrence of this tumor, incidence of FISAS over 
the past 20 years has not changed, still representing 15% of feline cutaneous masses.12 These 
tumors can be very challenging to treat, as they are characterized by rapid growth and non-
selective penetration into surrounding tissues and organs.4,13-15 Due to their infiltrative nature, 
recent studies suggest 5 cm lateral margins and 2 deep tissue planes are required for complete 
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surgical excision.14 Local recurrence has been reported in 19-22% of sites with microscopic 
tumor-free margins compared to 58-69% recurrence for sites without tumor-free margins.13,14 
Complete surgical excision of the tumor affords the best prognosis, but often requires radical 
surgery including thoracic or abdominal wall excision, amputation or hemipelvectomy, or 
removal of the scapula or dorsal spinous processes.5,14-16 Although adjuvant radiation therapy 
improves prognosis, many cats do not receive optimum treatment due to cost, invasiveness, or 
lack of access to a veterinary specialist.14,16 The mean time to tumor recurrence for such cats has 
been reported to be only 66 days, and the time to recurrence is shorter with each successive 
surgery, suggesting that incomplete excision may select for survival of a more aggressive 
population of cancer cells.16 Unfortunately, most tumors recur within 1-2 years of treatment and 
are uniformly fatal despite efforts to manage the recurrence.16   
 
The studies outlined in the previous chapters document the characteristics of release of 
carboplatin from carboplatin- impregnated CSH beads in vitro. Our data reveal that carboplatin-
impregnated CSH beads release carboplatin locally at levels greater than those achieved in 
plasma with IV administration of a single dose. Implanta tion of carboplatin- impregnated CSH 
beads at the time of radical surgery may introduce sufficiently high concentrations of carboplatin 
to the surgical site to result in cytotoxicity of cancer cells. This treatment may drastically 
improve survival outcomes by delivering high concentrations of carboplatin directly to the site of 
greatest need, the extirpated tumor bed. In one study, horses with cutaneous tumors such as soft 
tissue sarcoma and squamous cell carcinoma were treated with bead implantation alone, without 
removal of the mass if the mass was <1.5 cm diameter, or with marginal removal of larger 
masses and implantation of beads. Two years after bead implantation, 40/48 of horses showed no 
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signs or recurrence.1 In another study, platinum-containing CSH beads were implanted in the 
wound following wide surgical excision of soft tissue sarcomas. Thirteen of 23 tumors did not 
recur, and overall median disease-free interval was not reached.1 These findings suggest that for 
cats not undergoing radical surgery for FISAS, implantation of carboplatin- impregnated CSH 
beads may be performed alone or in combination with a more marginal, less invasive surgery. 
However, before carboplatin-impregnated CSH beads may be used in clinically-ill cats, studies 
are needed to determine I) the efficacy of carboplatin- impregnated CSH beads against FISAS 
cells in vitro (the IC50 of carboplatin for FISAS cells), II) the distribution of carboplatin in a three 
dimensional space after diffusion from the CSH bead and III) the in vivo pharmacokinetics and 
safety profile of carboplatin- impregnated CSH beads when implanted subcutaneously into cats. 
 
Funding has been secured for phases I and II of this study through an American College of 
Veterinary Surgeons Foundation grant. In phase I, a controlled, experimental study will be 
performed to evaluate the in vitro cytotoxic effects of carboplatin- impregnated CSH beads against 
FISAS cell lines in culture. Five FISAS cell lines will be treated with concentrations of carboplatin 
ranging from 5-450 μM derived from carboplatin- impregnated CSH beads. Cell prolifera t ion 
assays and apoptosis analyses will be performed to identify the carboplatin concentration needed 
to minimally result in 50% inhibition of cell growth or cytotoxicity of FISAS cells (IC50). In phase 
II, an agarose gel tissue phantom will be used to approximate spatial distribution of carboplatin 
from carboplatin- impregnated CSH beads. In phase III of the study,  carboplatin-impregnated CSH 
beads will be implanted subcutaneously in 4 healthy cats to determine the pharmacokinetic (PK) 
and safety profile of carboplatin- impregnated CSH beads in cats. Blood samples for platinum and 
PK evaluation will be taken at 1, 2, 3, 6, 12, and 24 hours and 2, 3, 7, 14, and 21 days. Small, 4-
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mm subcutaneous tissue samples obtained at 3, 7, 14, and 21 days will be evaluated 
histopathologically for signs of local toxicity and for platinum content by inductively coupled 
plasma-mass spectrometry (ICP-MS). 
 
Preliminary data from one FISAS cell line indicate that the IC50s for FISAS cells and carboplatin 
are within the range of concentrations released by carboplatin- impregnated CSH beads in vitro. It 
is expected that carboplatin concentrations released from carboplatin- impregnated CSH beads will 
be sufficiently toxic to FISAS cell cultures to achieve at least 50% growth inhibition or cytotoxic ity 
of cells. It is also expected that following implantation in cats, concentrations of carboplatin within 
tissues in proximity of beads will exceed the IC50. Finally, it is expected that neither significant 
systemic concentrations of platinum nor local toxicity will be observed associated with bead 
implantation in cats. 
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